scholarly journals Relationship among the leptin-to-adiponectin ratio, systemic inflammation, and anisocytosis: a plausible pathophysiological mechanism of a novel cardiovascular risk marker

2020 ◽  
Vol 78 (5) ◽  
pp. 381-382
Author(s):  
Patricio López-Jaramillo ◽  
Diego Gómez-Arbeláez ◽  
Jose López-López
Keyword(s):  
Cardiovascular Risk ◽  
Systemic Inflammation ◽  
Risk Marker ◽  
Pathophysiological Mechanism ◽  
Cardiovascular Risk Marker

scholarly journals MP392IMPACT OF HYPERPHOSPHATEMIA CORRECTIVE THERAPY ON CARDIOVASCULAR RISK MARKER - FGF-23 IN CHRONIC KIDNEY DISEASE PATIENTS

2016 ◽  
Vol 31 (suppl_1) ◽  
pp. i469-i470
Author(s):  
Yuriy Milovanov ◽  
Anna Dudareva ◽  
Ludmila Milovanova ◽  
Lidia Kozlovskaya ◽  
Nikolay Mukhin ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Cardiovascular Risk ◽  
Kidney Disease ◽  
Risk Marker ◽  
Fgf 23 ◽  
Cardiovascular Risk Marker

scholarly journals MP263IMPACT OF TRADITIONAL ANTIHYPERTENSIVE THERAPY ON CARDIOVASCULAR RISK MARKER - KLOTHO IN CHRONIC KIDNEY DISEASE PATIENTS

2016 ◽  
Vol 31 (suppl_1) ◽  
pp. i427-i428
Author(s):  
Svetlana Milovanova ◽  
Nikolay Mukhin ◽  
Ludmila Milovanova ◽  
Lidia Kozlovskaya ◽  
Victor Fomin
Keyword(s):  
Chronic Kidney Disease ◽  
Cardiovascular Risk ◽  
Kidney Disease ◽  
Antihypertensive Therapy ◽  
Risk Marker ◽  
Cardiovascular Risk Marker

scholarly journals A New Cardiovascular Risk Marker in Men with Hypogonadism: Alanine Aminotransferase

2019 ◽  
Vol 23 (4) ◽  
pp. 197-205
Author(s):  
Murat ŞAHİN ◽  
Ayten OĞUZ ◽  
Dilek TÜZÜN ◽  
Semiha ÇALKAYA ◽  
Kamile GÜL
Keyword(s):  
Cardiovascular Risk ◽  
Alanine Aminotransferase ◽  
Risk Marker ◽  
Cardiovascular Risk Marker

Asymptomatic hyperuricaemia: to treat or not to treat?

2016 ◽  
Author(s):  
Thomas Bardin
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Cardiovascular Risk ◽  
Lifestyle Changes ◽  
Risk Marker ◽  
Randomized Control Trials ◽  
Frequent Finding ◽  
Randomized Control ◽  
Lowering Drug ◽  
Cardiovascular Risk Marker

Asymptomatic hyperuricaemia is a frequent finding and evidence is growing that it could be an independent cardiovascular risk marker. Recent studies challenge the dogma not to treat asymptomatic hyperuricaemia. However, no urate-lowering drug has been approved for the management of asymptomatic hyperuricaemia in Western countries, because the lack of large randomized control trials precludes assessment of benefits. Asymptomatic hyperuricaemia should lead to lifestyle changes and promote the search for cardiovascular risk factors amenable to therapy, in order to lower the hazards of cardiovascular disease and mortality.

scholarly journals Vascular Age as a Cardiovascular Risk Marker in Asymptomatic Patients with Type 2 Diabetes

2020 ◽  
Vol Volume 13 ◽  
pp. 2505-2514
Author(s):  
Catia Cristina Silva Sousa Vergara Palma ◽  
Pablo Moura Lopes ◽  
Eliete Leao Clemente Silva ◽  
Maria de Fátima da Matta Bevilaqua ◽  
Alfredo de Souza Bomfim ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Risk Marker ◽  
Asymptomatic Patients ◽  
Vascular Age ◽  
Cardiovascular Risk Marker
Sign in / Sign up

Export Citation Format

Share Document